Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene.

Diabetic medicine : a journal of the British Diabetic Association - 1 Oct 2003

Owen Katharine R, Donohoe Mollie, Ellard Sian, Hattersley Andrew T

Abstract excerpt

BACKGROUND: Familial partial lipodystrophy (FPLD) is a monogenic form of diabetes characterised by a dominantly inherited disorder of adipose tissue associated with the loss of subcutaneous fat from the limbs and trunk, with excess fat deposited around the face and neck. The lipodystrophy causes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycated Hemoglobin
Share to Hypoglycemic Agents
Share to Lamin Type A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leptin

Share to Receptors, Cytoplasmic and Nuclear

Share to Rosiglitazone

Share to Skinfold Thickness

Share to Thiazolidinediones

Source

Identifiers

PMID: 14510863
DOI: 10.1046/j.1464-5491.2003.01034.x

Genes

LMNA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-14510863-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene.PMID 14510863Read ↗

Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series.Semantic proximity Read ↗

Efficacy of leptin therapy in the different forms of human lipodystrophy.Semantic proximity Read ↗

LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response.Semantic proximity Read ↗

A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies.Semantic proximity Read ↗

Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.Semantic proximity Read ↗

Familial Generalized and Partial Lipodystrophies Due to Rare Biallelic Variants in LMNA.Semantic proximity Read ↗

Familial partial lipodystrophy associated with the heterozygous LMNA mutation 1445G>A (Arg482Gln) in a Polish family.Semantic proximity Read ↗

Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.Semantic proximity Read ↗

Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome.Semantic proximity Read ↗

Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene.Semantic proximity Read ↗

Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.Semantic proximity Read ↗

Metreleptin as A Rescue Therapy in A Patient With A Novel Mutation for Familial Partial Lipodystrophy Type 3, Originally Presenting as Type 1 Diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.